(Q40575774)

21 September 2017

title

Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer (English)

1 reference

21 September 2017

1 reference

1 reference

1 reference

T Kasai

1

1 reference

21 September 2017

M Oka

2

1 reference

21 September 2017

H Soda

3

1 reference

21 September 2017

J Tsurutani

4

1 reference

21 September 2017

M Fukuda

5

1 reference

21 September 2017

Y Nakamura

6

1 reference

21 September 2017

S Kawabata

7

1 reference

21 September 2017

K Nakatomi

8

1 reference

21 September 2017

S Nagashima

9

1 reference

21 September 2017

H Takatani

10

1 reference

21 September 2017

M Fukuda

11

1 reference

21 September 2017

A Kinoshita

12

1 reference

21 September 2017

S Kohno

13

1 reference

21 September 2017

publication date

1 September 2002

1 reference

21 September 2017

number of pages

8

1 reference

European Journal of Cancer

inferred from page(s)

published in

1 reference

21 September 2017

volume

38

1 reference

21 September 2017

issue

14

1 reference

21 September 2017

page(s)

1871-1878

1 reference

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900231-9

7 January 2021

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900231-9

7 January 2021

New combinations in the treatment of lung cancer: a time for optimism

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900231-9

7 January 2021

Promotion of microtubule assembly in vitro by taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900231-9

7 January 2021

Taxol stabilizes microtubules in mouse fibroblast cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900231-9

7 January 2021

On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900231-9

7 January 2021

Regional lymph node classification for lung cancer staging

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900231-9

7 January 2021

High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-pha

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900231-9

7 January 2021

Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900231-9

7 January 2021

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900231-9

7 January 2021

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900231-9

7 January 2021

Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900231-9

7 January 2021

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900231-9

7 January 2021

Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900231-9

7 January 2021

Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900231-9

7 January 2021

Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900231-9

7 January 2021

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900231-9

7 January 2021

Human liver microsomal metabolism of paclitaxel and drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900231-9

7 January 2021

10.1016/S0959-8049(02)00231-9

Identifiers

DOI

1 reference

21 September 2017

1 reference